Last 36 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.22 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 2.90 | 2.33 | 3.50 | 5.46 | 5.12 | 7.25 | 11.48 | 5391.33 | — | — | 35.12 | — | 249.62 | — | 61.89 | 14.55 | 20.61 | — | — | 525.46 | 505.80 |
| — | -67.9% | -69.5% | -99.9% | — | — | -67.3% | — | — | — | -43.3% | — | +1111.4% | — | — | -97.2% | -95.9% | — | — | +52.1% | +126.9% | |
| P/B Ratio | 1.91 | 5.69 | 3.37 | 2.97 | 1.63 | 1.75 | 1.11 | 1.46 | 2.03 | 1.75 | 2.44 | 10.05 | 2.25 | 1.80 | 1.20 | 0.75 | 1.21 | 1.20 | 1.40 | 1.21 | 1.95 |
| — | +224.9% | +203.6% | +103.2% | -19.3% | -0.1% | -54.4% | -85.4% | -9.8% | -2.8% | +103.2% | +1248.7% | +85.3% | +50.4% | -14.3% | -38.3% | -37.9% | -27.6% | +17.1% | -54.6% | -23.8% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -27.8% | 55.2% | 6.3% | -4.3% | -35.1% | -16.8% | -99.9% | -476810.3% | — | — | 82.1% | — | -275.6% | — | -47.0% | 55.2% | -1488.5% | — | — | -21919.4% | -13583.1% |
| — | +427.9% | +106.3% | +100.0% | — | — | -221.6% | — | — | — | +274.8% | — | +81.5% | — | — | +100.3% | +89.0% | — | — | -131.1% | -181.0% | |
| Operating Margin | -372.4% | -95.9% | -227.0% | -298.3% | -337.9% | -292.6% | -726.3% | -832503.4% | — | — | -384.1% | — | -10849.3% | — | -2738.4% | -792.1% | -3424.5% | — | — | -48211.7% | -30782.6% |
| — | +67.2% | +68.7% | +100.0% | — | — | -89.1% | — | — | — | +86.0% | — | -216.8% | — | — | +98.4% | +88.9% | — | — | -126.4% | -174.3% | |
| Net Margin | -381.4% | -85.6% | -273.1% | -371.9% | -373.3% | -229.0% | -781.1% | -95193.1% | — | — | -522.1% | — | -11292.9% | — | -3081.3% | -704.6% | -1805.3% | — | — | -23147.8% | -14403.0% |
| — | +62.6% | +65.0% | +99.6% | — | — | -49.6% | — | — | — | +83.1% | — | -525.5% | — | — | +97.0% | +87.5% | — | — | -118.2% | -162.5% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -95.2% | -42.6% | -49.9% | -40.7% | -25.9% | -13.4% | -17.6% | -6.1% | -16.3% | -10.5% | -15.2% | -52.9% | -22.4% | -18.4% | -14.1% | -11.7% | -22.8% | -17.3% | -12.7% | -14.9% | -12.9% |
| — | -218.9% | -183.9% | -566.1% | -58.3% | -27.2% | -15.7% | +88.4% | +27.0% | +42.8% | -7.9% | -350.9% | +1.7% | -6.0% | -11.0% | +21.5% | -77.0% | -52.3% | +2.9% | +22.2% | +14.5% | |
| ROA | -42.0% | -7.7% | -12.8% | -14.4% | -11.4% | -6.5% | -9.2% | -3.4% | -9.8% | -6.6% | -8.3% | -19.8% | -10.7% | -10.0% | -8.4% | -7.1% | -14.8% | -12.4% | -9.6% | -11.9% | -10.8% |
| — | -17.4% | -39.8% | -320.6% | -17.2% | +1.6% | -11.2% | +82.6% | +8.7% | +33.6% | +1.5% | -176.3% | +27.7% | +19.4% | +13.0% | +39.8% | -36.6% | -27.2% | +6.8% | +15.4% | +8.9% | |
| ROIC | -62.3% | -146.8% | -18.5% | -16.2% | -20.2% | -10.5% | -11.7% | -96.9% | -44.8% | -41.7% | -213.8% | — | — | -122.2% | -35.8% | -34.4% | -92.5% | -51.1% | -44.4% | -79.2% | -59.5% |
| — | -1296.6% | -58.3% | +83.3% | +54.9% | +74.8% | +94.5% | — | — | +65.9% | -497.9% | — | — | -139.3% | +19.5% | +56.6% | -55.6% | +15.3% | +17.9% | -35.9% | +3.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.97 | 1.12 | 0.73 | 1.97 | 0.25 | 0.19 | 0.84 | 0.12 | 0.63 | 0.55 | 0.48 | 0.48 | 0.29 | 0.22 | 0.59 | 0.50 | 0.42 | 0.32 | 0.25 | 0.22 | 0.09 |
| — | +499.1% | -12.4% | +1502.6% | -60.7% | -65.9% | +74.4% | -74.1% | +117.3% | +146.2% | -18.8% | -5.5% | -30.7% | -29.7% | +136.0% | +131.6% | +370.5% | +295.4% | +223.6% | -15.8% | -60.1% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.94 | 4.89 | 5.80 | 5.94 | 6.19 | 8.43 | 9.24 | 10.88 | 13.69 | 18.50 | 18.25 | 6.15 | 8.16 | 8.60 | 9.94 | 9.18 | 5.47 | 7.29 | 10.73 | 12.15 | 6.84 |
| — | -42.0% | -37.3% | -45.4% | -54.7% | -54.5% | -49.3% | +76.8% | +67.6% | +115.1% | +83.6% | -33.0% | +49.3% | +18.0% | -7.4% | -24.4% | -20.0% | -23.7% | +14.0% | +110.7% | -7.9% | |
| Quick Ratio | 5.48 | 4.40 | 5.28 | 5.48 | 5.86 | 8.07 | 9.02 | 10.81 | 13.69 | 18.50 | 18.25 | 6.15 | 8.16 | 8.60 | 9.94 | 9.18 | 5.47 | 7.29 | 10.73 | 12.15 | 6.84 |
| — | -45.5% | -41.5% | -49.3% | -57.2% | -56.4% | -50.5% | +75.7% | +67.6% | +115.1% | +83.6% | -33.0% | +49.3% | +18.0% | -7.4% | -24.4% | -20.0% | -23.7% | +14.0% | +110.7% | -7.9% | |
| Interest Coverage | -7.08 | -13.45 | -5.37 | -3.01 | -6.47 | — | -5.70 | -2.46 | -6.33 | -4.72 | -1.73 | -1.15 | -8.48 | -8.07 | -7.12 | -6.69 | -23.51 | -26.37 | -22.85 | -42.58 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 36 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AUTL stock.
Autolus Therapeutics plc's current P/E is -1.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Autolus Therapeutics plc's current operating margin is -372.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Autolus Therapeutics plc's business trajectory between earnings reports.